LifeSci Capital Reaffirms Their Buy Rating on Immunovant (IMVT)

LifeSci Capital analyst Sam Slutsky maintained a Buy rating on Immunovant (IMVT – Research Report) today and set a price target of $34.00....

Related Keywords

New York ,United States ,Ventyx Biosciences ,Sam Slutsky ,Immunovant Inc , ,Lifesci Capital ,Research Report ,Strong Buy ,